Document is current

Article History

Received: 19 June 2019

Accepted: 6 December 2019

First Online: 7 January 2020

Ethics approval and consent to participate

: The protocol of this study was approved by the Medical Ethics Committee of Amsterdam UMC (MEC 2013.393) and the competent authority (CCMO NL45933.029.13). The study was conducted according to the Dutch Act on Medical Research involving Human Subjects (WMO) and in compliance with good clinical practice (ICH-GCP). All patients gave written informed consent.

: Not applicable

: PS has acquired grant support (for the institution) from GE Healthcare, Nutricia Research, Piramal, and MERCK. In the past, he has received consultancy/speaker fees (paid to the institution) from Lilly, Biogen, Novartis, Probiodrug, Roche, and EIP Pharma. FB serves as a consultant for Biogen, Janssen, Bayer, Merck, Roche, Novartis, Lundbeck, and IXICO. He has received sponsoring from EU-H2020, IMDI, SMSR, TEVA, Novartis, Toshiba, and IMI and is supported by NIHR-UCLH Biomedical Research Center. WF performs contract research for Boehringer Ingelheim and has been an invited speaker at Boehringer Ingelheim. Research programs of WF have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, Cardiovasculair Onderzoek Nederland, stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, and Combinostics. All funding is paid to her institution. NP serves on the advisory board of Boehringer Ingelheim and Probiodrug and on the DSMB of Abbvie’s M15-566 trial. NP is the CEO and co-owner of the Brain Research Center, Amsterdam, The Netherlands. He received research support from Alzheimer Nederland (STREAM-VCI project number WE.03-2012-02). The other authors declare that they have no competing interests.